On 14th December 2006, Veeda Clinical Research completed the acquisition of DICE, a CRO based in Brussels, Belgium.

Veeda Clinical Research is a leading European/Indian Contract Research Organisation (CRO) with over two decades of experience in the early clinical development of new drugs. The acquisition of DICE, a highly specialized CRO with 15 years of experience in data management, biostatistics, statistical analysis and medical writing for clinical trials, enables Veeda CR to offer the biopharmaceutical market an ever greater depth of scientific expertise, delivered from sites in the UK, mainland Europe and the Indian sub continent.

Marie-Paule Derde, Director of DICE, will remain with the Company with responsibility for the day to day operation of the business. She will continue being assisted by Professor Leonard Kaufman, head of Biostatistics and Medical Informatics of the University of Brussels.

Marie-Paule Derde is excited by the coming together of the two companies and the potential for growth, “the acquisition of DICE by Veeda CR provides exciting expansion opportunities, both in Europe and through taking advantage of the high capacity and cost advantages of India” said MS Derde

Veeda CR sees great potential in building on the data management expertise of the newly acquired DICE team and sees as investment in the infrastructure of the Brussels operation as a vital first step in the planned growth of its CDM activity.

Apurva Shah, Veeda Director, said “this is an important and exciting time for Veeda CR and our clients will immediately benefit from the high quality service of DICE as part of an ever more comprehensive service offering from Veeda CR”

Veeda Clinical Research is a specialist CRO with top class clinical pharmacology units equipped with a total of 185 beds between both units in Plymouth, UK and Ahmedabad, India. The Veeda CR service blends 20 years of phase I expertise in Europe with the substantial benefits, both intellectual and economic, of the Indian sub Continent. With the acquisition of DICE, Veeda CR will be well placed to deliver cost effective, timely research solutions to the pharmaceutical and biotechnology industries worldwide.

Veeda CR has dedicated clinical pathology, bioanalysis, biomarker and immunogenicity laboratory services which are GLP accredited and has access to an extensive database of volunteers. Veeda CR can locate the right trial in the right place, with the UK Unit offering specialized, highly demanding studies and the Indian Unit offering vast populations, excellent turnaround times and considerable economies.